Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders

Diane J. Nugent(Children's Hospital of Orange County), Suchitra S. Acharya(Northwell Health), Kimberly J. Baumann(Fairview Health Services), Camille L. Bedrosian(Ultragenyx Pharmaceutical (United States)), Rebecca Bialas(Immune Deficiency Foundation), Kai Brown(National Hemophilia Foundation), Deya Corzo(Io Therapeutics (United States)), Amar Haidar(Expert System (Italy)), Catherine P.M. Hayward(Hamilton Regional Laboratory Medicine Program), Peter Marks(Center for Biologics Evaluation and Research), Marzia Menegatti(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Margaret E. Miller(Providence Alaska Medical Center), Kate Nammacher(National Hemophilia Foundation), Roberta Palla(University of Milan), Skye Peltier(Fairview Health Services), Rajiv K. Pruthi(Mayo Clinic), Michael Recht(Oregon Health & Science University), Benny Sørensen(Forma Therapeutics (United States)), Michael D. Tarantino(Bleeding & Clotting Disorders Institute), Alisa S. Wolberg(University of North Carolina at Chapel Hill), Amy D. Shapiro(Indiana Hemophilia and Thrombosis Center)
Expert Review of Hematology
March 15, 2023
Cited by 17Open Access
Full Text

Abstract

BACKGROUND: Ultra-rare inherited bleeding disorders (BDs) present important challenges for generating a strong evidence foundation for optimal diagnosis and management. Without disorder-appropriate treatment, affected individuals potentially face life-threatening bleeding, delayed diagnosis, suboptimal management of invasive procedures, psychosocial distress, pain, and decreased quality-of-life. RESEARCH DESIGN AND METHODS: The National Hemophilia Foundation (NHF) and the American Thrombosis and Hemostasis Network identified the priorities of people with inherited BDs and their caregivers, through extensive inclusive community consultations, to inform a blueprint for future decades of research. Multidisciplinary expert Working Group (WG) 3 distilled highly feasible transformative ultra-rare inherited BD research opportunities from the community-identified priorities. RESULTS: WG3 identified three focus areas with the potential to advance the needs of all people with ultra-rare inherited BDs and scored the feasibility, impact, and risk of priority initiatives, including 13 in systems biology and mechanistic science; 2 in clinical research, data collection, and research infrastructure; and 5 in the regulatory process for novel therapeutics and required data collection. CONCLUSIONS: Centralization and expansion of expertise and resources, flexible innovative research and regulatory approaches, and inclusion of all people with ultra-rare inherited BDs and their health care professionals will be essential to capitalize on the opportunities outlined herein.


Related Papers

No related papers found

Powered by citation graph analysis